Medical prescription

The Association of American Physicians and Surgeons (AAPS) Challenges the American Medical Association (AMA) on Efforts to Suppress Ivermectin Use in COVID

Retrieved on: 
Saturday, September 4, 2021

TUCSON, Ariz., Sept. 04, 2021 (GLOBE NEWSWIRE) -- In a letter to American Medical Association president Gerald Harmon , M.D., the Association of American Physicians and Surgeons (AAPS) raises questions concerning the AMAs startling and unprecedented position that American physicians should immediately stop prescribing, and pharmacists should stop honoring their prescriptions for ivermectin for COVID-19 patients.

Key Points: 
  • TUCSON, Ariz., Sept. 04, 2021 (GLOBE NEWSWIRE) -- In a letter to American Medical Association president Gerald Harmon , M.D., the Association of American Physicians and Surgeons (AAPS) raises questions concerning the AMAs startling and unprecedented position that American physicians should immediately stop prescribing, and pharmacists should stop honoring their prescriptions for ivermectin for COVID-19 patients.
  • AAPS points out that many physicians disagree with the AMA, writing around 88,000 ivermectin prescriptions per week.
  • Also the Chairman of the Tokyo Medical Association , Haruo Ozaki, recommended that all doctors in Japan immediately begin using ivermectin to treat COVID.
  • The Association of American Physicians and Surgeons has represented physicians in all specialties since 1943.

Truveris Appoints Nanette Oddo President and Chief Executive Officer

Retrieved on: 
Wednesday, August 4, 2021

Truveris announced today that Nanette Oddo has been named President and Chief Executive Officer.

Key Points: 
  • Truveris announced today that Nanette Oddo has been named President and Chief Executive Officer.
  • A veteran industry leader, Ms. Oddo previously served as Truveris Chief Strategy Officer, spearheading the Companys strategic vision during a period of consistent innovation and growth.
  • "Truveris uniquely bends the cost curve to improve the accessibility and affordability of prescription medications, one of the critical challenges facing healthcare today," said Oddo.
  • Prior to Truveris, Oddo spent twelve years in various leadership roles at Phreesia, the leading intake and patient engagement software solution.

RXNT Named "Best E-Prescribing Software" of 2021

Retrieved on: 
Wednesday, August 4, 2021

ANNAPOLIS, Md., Aug. 4, 2021 /PRNewswire-PRWeb/ -- RXNT , an industry-leading provider of cloud-based ambulatory healthcare software, today announced that it has been selected as one of the Best E-Prescribing Software companies of 2021 by Digital.com, an independent review website for small businesses and startups.

Key Points: 
  • ANNAPOLIS, Md., Aug. 4, 2021 /PRNewswire-PRWeb/ -- RXNT , an industry-leading provider of cloud-based ambulatory healthcare software, today announced that it has been selected as one of the Best E-Prescribing Software companies of 2021 by Digital.com, an independent review website for small businesses and startups.
  • The research team conducted over 40 hours of assessment on more than 75 e-prescribing software companies from across the web to create the report.
  • "We are excited to once again stand out as a leader in the growing and evolving HealthIT market," said Randy Boldyga, CEO and President of RXNT.
  • RXNT was recognized based on its core features like medication history, clinical alerts, prescription cancellation and renewals, and refill management.

RxRevu and FDB Partner to Accelerate Delivery of Real-Time Prescription Benefit Data to the Point of Care

Retrieved on: 
Tuesday, August 3, 2021

"The RxRevu and FDB partnership is an exciting step forward in delivering real-time, patient-specific cost and coverage data where it matters most," said Kyle Kiser, Chief Executive Officer at RxRevu.

Key Points: 
  • "The RxRevu and FDB partnership is an exciting step forward in delivering real-time, patient-specific cost and coverage data where it matters most," said Kyle Kiser, Chief Executive Officer at RxRevu.
  • RxRevu's Real-Time Prescription Benefit solution SwiftRx Direct delivers patient-specific pharmacy benefit information to EHR workflows via direct connections with prominent pharmacy benefit managers.
  • By leveraging FDB's commercial channels, RxRevu will expand the delivery of its prescription coverage and cost data as a supplementary service.
  • FDB will offer RxRevu's prescription cost and coverage solution to current and future hospital, health system, and EHR clients.

Levitee Labs Acquires Three Specialized Alberta Pharmacies

Retrieved on: 
Thursday, July 29, 2021

Each of the Companies operates a pharmacy in Alberta specialized in filling prescriptions for medications used to treat people with substance use disorders, mental health conditions and chronic pain.

Key Points: 
  • Each of the Companies operates a pharmacy in Alberta specialized in filling prescriptions for medications used to treat people with substance use disorders, mental health conditions and chronic pain.
  • Purchasing these pharmacies was part and parcel to our strategy to be a vertically integrated company focused on substance abuse and chronic conditions, said Pouya Farmand, Chief Executive Officer at Levitee.
  • Adding three specialized pharmacies gives us a commanding position to serve Albertans in need, from curating treatment programs on-site or remotely to filling prescriptions and delivering them directly to patients homes.
  • Levitee Labs is establishing itself as a leader in the integrative wellness space.

'What the Health?': The Drug Price Dilemma

Retrieved on: 
Friday, July 30, 2021

That is because the dilemma faced by many Americans is the struggle of paying the price for filling their prescriptions.

Key Points: 
  • That is because the dilemma faced by many Americans is the struggle of paying the price for filling their prescriptions.
  • Among other G7 nations the UK, France, and Italy have the lowest prescription drug prices.
  • Canada's drug prices are higher, but still considerably less than the cost for the same medications in the USA.
  • That improved access has yet to be seen, and so the dilemma of figuring out ways to afford prescription medication continues for many Americans.

Optinose Announces Preliminary Second Quarter 2021 XHANCE Net Revenue of $18.4 Million

Retrieved on: 
Wednesday, July 28, 2021

YARDLEY, Pa., July 28, 2021 (GLOBE NEWSWIRE) -- Optinose (NASDAQ:OPTN), a pharmaceutical company focused on patients treated by ear, nose and throat (ENT) and allergy specialists, today announced preliminary XHANCE® (fluticasone propionate) net product revenue of $18.4 million for the three months ended June 30, 2021. This represents a 79% increase compared to the three months ended June 30, 2020, and a 67% increase compared to the three months ended March 31, 2021. The Company expects XHANCE net product revenue for the full year of 2021 to be at least $80 million.

Key Points: 
  • The Company expects XHANCE net product revenue for the full year of 2021 to be at least $80 million.
  • In addition, the number of XHANCE prescriptions increased by 33% from 62,500 in the second quarter 2020 to 82,900 in the second quarter 2021 based on third-party prescription data and data from XHANCE preferred pharmacy network partners.
  • XHANCE net revenue per prescription increased 35% from $164 in the second quarter 2020 to $221 in the second quarter 2021 based on preliminary second quarter net product revenue of $18.4 million.
  • We are pleased with the growth in demand for XHANCE and increased net product revenue per prescription based on preliminary second quarter net product revenue of $18.4 million, stated CEO Peter Miller.

Humana Ranks #1 for Customer Satisfaction for Mail Order for Four Consecutive Years in J.D. Power U.S. Pharmacy Study

Retrieved on: 
Wednesday, July 28, 2021

Humana Pharmacy, a division of Humana Inc. (NYSE: HUM), received the highest ranking in Mail Order Pharmacy customer satisfaction for the fourth year in a row in the J.D.

Key Points: 
  • Humana Pharmacy, a division of Humana Inc. (NYSE: HUM), received the highest ranking in Mail Order Pharmacy customer satisfaction for the fourth year in a row in the J.D.
  • View the full release here: https://www.businesswire.com/news/home/20210728005199/en/
    Humana Ranks #1 for Customer Satisfaction for Mail Order for Four Consecutive Years in J.D.
  • Power U.S. Pharmacy Study (Photo: Business Wire)
    With a score of 906 out of 1,000, Humana ranked first in all four of the studys Mail Order Pharmacy categories: prescription ordering and filling process, cost competitiveness, prescription delivery, and customer service experience.
  • Humana Pharmacy takes pride in providing a hassle and worry-free experience as we bring the pharmacy to our customers, shipping medications both safely and on-time.

Agile Therapeutics Reports Second Quarter 2021 Financial Results

Retrieved on: 
Monday, July 26, 2021

PRINCETON, N.J., July 26, 2021 (GLOBE NEWSWIRE) -- Agile Therapeutics, Inc. (Nasdaq: AGRX), a women's healthcare company, today reported financial results for the three months ended June 30, 2021 and provided a corporate update.

Key Points: 
  • Management to Host Conference Call Today, Monday, July 26, 2021 at 4:30 p.m. EDT
    PRINCETON, N.J., July 26, 2021 (GLOBE NEWSWIRE) -- Agile Therapeutics, Inc.(Nasdaq: AGRX), a women's healthcare company, today reported financial results for the three months ended June 30, 2021 and provided a corporate update.
  • The theme of Agiles 2021 second quarter is growth.
  • Recent Corporate Developments and Second Quarter 2021 Results:
    During the second quarter 2021, total prescriptions were 5,027, representing an increase of 171% from the end of the first quarter.
  • As of June 30, 2021, 2,033 prescriptions dispensed at pharmacies were refills, which represented an increase of 355% during the second quarter.

Bumped Study Shows Walgreens Customers Rewarded in Walgreens Stock Spend 30% More Monthly, Less with Drug Store Competitors

Retrieved on: 
Thursday, July 22, 2021

Over a two-year data study, Bumped automatically rewarded users in fractional shares of Walgreens stock (WBA) when they made purchases or picked up their prescriptions at Walgreens.

Key Points: 
  • Over a two-year data study, Bumped automatically rewarded users in fractional shares of Walgreens stock (WBA) when they made purchases or picked up their prescriptions at Walgreens.
  • On average, customers who became owners of their drug store brand spent about 30% more monthly, and visited with them 32% more often.
  • "We were excited to see the share of wallet shift in this category given the broad competitive landscape for drug store spend," says David Nelsen, CEO & Founder of Bumped.
  • The Bumped pilot ran for two years and rewarded over 13,000 US consumers in fractional stock rewards when they spent at more than 80 brands.